share_log

Guo Guangchang: Fosun Firmly Advances Its Globalization Strategy

Guo Guangchang: Fosun Firmly Advances Its Globalization Strategy

郭广昌:复星坚定推进全球化策略
PR Newswire ·  07/23 05:45

HONG KONG, July 23, 2024 /PRNewswire/ -- "In the future, Fosun will continue to firmly advance its globalization strategy, transforming its globalization capability into sustained profit growth." Guo Guangchang, Chairman of Fosun International, said at the 2024 Fosun Semi-Annual Working Meeting on 20 July 2024. "Fosun's globalization is not a strategy which commences today, but has been going on for a very long period of time. We have become one of the few Chinese enterprises rooted in China with the capability to operate globally, that we are particularly proud of it."

"未来,复星将继续坚定推进其全球化策略,将其全球化能力转化为持续的利润增长。"复星国际主席郭广昌在2024年7月20日的2024年复星半年度工作会议上说。"复星的全球化不是今天开始的策略,而是已经进行了很长一段时间。我们已成为中国企业中少数在中国扎根并具备全球运营能力的企业之一,我们为此感到特别自豪。"

Fosun has developed along the path of globalization for nearly 17 years. Fosun International started its globalization journey in 2007 when it was listed in Hong Kong. In the following decade, Fosun seized opportunities, continuously allocated global high-quality assets, expanded its diversified businesses, strengthened its industrial chain, and gradually built a global industrial ecosystem in line with its development logic. Today, Fosun has a profound business presence in more than 35 countries and regions around the world. In 2023, Fosun's overseas revenue reached RMB89.2 billion, accounting for 45% of its total revenue, with a 10-year compound annual growth rate of 55%.

复星已发展了近17年的全球化之路。复星国际在2007年在香港上市时开始了其全球化之旅。在接下来的十年,复星抓住机遇,不断配置全球高质量资产,扩大其多元化业务,加强其产业链,并根据其发展逻辑逐步建立了全球产业生态系统。如今,复星在全球35多个国家和地区拥有深入的业务布局。2023 年,复星海外收入达到892亿元,占总收入的45%, 10年复合年增长率达到55%。

With Fosun's businesses spread across the globe, how can it further integrate different industries and resources in various countries and regions, enhance the global operation capabilities of its member companies, and tap into potential values?

复星的业务遍布全球,如何进一步整合各国和地区不同的行业和资源,增强其成员公司的全球运营能力,并发掘潜在价值?

Guo Guangchang believes that the most important thing is to transform globalization capabilities into dividends and profit growth. "The extent of global layout and globalization capability differ with our member companies and business units. We would like to see each business doing equally well. Besides the conventional overseas markets, it is hoped that competency would also be developed in the Middle East, Latin America, Southeast Asia and Africa."

郭广昌认为最重要的是将全球化能力转化为股息和利润增长。"全球布局和全球化能力在我们的成员公司和业务部门之间存在差异。我们希望看到每个业务都表现出色。除了传统的海外市场,我们希望在中东、拉美、东南亚和非洲等地区发展能力建设。"

Club Med, the French-born global "premium all-inclusive" holiday resort brand officially joined Fosun in 2015. Guo Guangchang said Fosun's successful acquisition of Club Med is an important milestone to the Group's globalization. With nearly ten years of profound operation through continuous development of the global market, Club Med has now become one of the most important sources of revenue and profit for its parent company Fosun Tourism Group.

法国诞生的全球"高端全包"度假胜地品牌Club Med于2015年正式加入复星。郭广昌说,复星成功收购Club Med 是集团全球化的一个重要里程碑。经过近十年的深入运作,通过不断发展全球市场,Club Med现已成为其母公司复星旅游文化的最重要的收入和利润来源之一。

After years of development, the gene of globalization has been deeply rooted in all of Fosun's business segments. Fosun Pharma is one of the earliest representatives of Fosun's member companies to "go global". As early as 2007, Fosun Pharma entered the African market as a leading developer and manufacturer of antimalarial drugs. Today, its sales network covers more than 30 African countries and regions. Empowered by Fosun under the global ecosystem, Fosun Pharma's world-engaging integrated innovative model is maturing progressively.

经过多年的发展,全球化基因已经深入到了复星的所有业务领域。复星医药是复星成员公司中最早的"走出去"代表之一。早在2007年,复星医药就作为一家领先的抗疟药物研发和生产商进入非洲市场。如今,它的销售网络覆盖了30多个非洲国家和地区。在复星的全球生态系统下,复星医药的全球一体化创新模式正在逐步成熟。

In June this year, Fosun Pharma announced its plan to privatise its subsidiary Shanghai Henlius. As an outstanding representative of domestically developed innovative drugs, Shanghai Henlius has developed a number of innovative drugs such as HANQUYOU and HANSIZHUANG, and its capabilities of manufacturing and commercializing self-developed innovative drugs to meet the needs of patients in different regions have gained high market recognition. For instance, HLX02 (trastuzumab, trade name: HANQUYOU in China, HERCESSI in the U.S. and Zercepac in Europe) is the first "China-made" monoclonal biosimilar approved in China, European Union, and U.S. and was approved to be marketed in more than 40 countries and regions around the world. In 2023, Shanghai Henlius became the first profit-making Hong Kong-listed "18A" biopharmaceutical company, achieving annual net profit of RMB546 million.

今年6月,复星医药宣布计划私有化其子公司复宏汉霖。作为国内自主开发创新药物的杰出代表,复宏汉霖研制了一批创新性药物,如HANQUYOU和HANSIZHUANG,并具备生产和商业化自行研发的创新药物以满足不同地区患者需求的能力,在市场上得到了很高的认可。例如,HLX02(曲妥珠单抗,商品名:中国的HANQUYOU,在美国的HERCESSI和欧洲的Zercepac)是首个获批在中国、欧洲和美国销售的"中国制造"单克隆生物类似物。在2023年,复宏汉霖成为首家实现港股18A生物医药公司的净利润达到5,4600万元的公司。

"Globalization must also be pursued by our overseas companies, Fidelidade is doing very good in this aspect." At the meeting on 20 July, Guo Guangchang included Fidelidade as one of the "honor companies" and encouraged more Fosun overseas member companies to expand their global businesses. Data shows that the global operation capability of Fidelidade remarkably enhanced after it has joined Fosun. Besides maintaining its leadership in Portugal, Fidelidade's premium percentage in overseas markets also increased from 6% in 2017 to 33% in 2023. With the steady expansion of its business scale, Fidelidade has continuously improved its profitability, achieving a net profit of EUR180 million in 2023.

"全球化也必须由我们的海外公司追求,保险业务Fidelidade在这方面做得很好。"在7月20日的会议上,郭广昌将Fidelidade作为"荣誉公司"之一,并鼓励更多复星海外成员公司扩展其全球业务。数据显示,Fidelidade加入复星后其全球运营能力显著提升。除了在葡萄牙保持领先地位外,Fidelidade在海外市场的保费比例也从2017年的6%增加到2023年的33%。随着业务规模的稳步扩大,Fidelidade的盈利能力不断提高,2023年实现了1.8亿欧元的净利润。

In response to repeated appeals for deglobalization recent years, Guo Guangchang said: "The main trend of opening up integration of globalization will remain unchanged in the long term, we believe Fosun has been persistently in doing the right thing and will continue to do so."

针对近年来反全球化的反复呼声,郭广昌表示: "长期来看,全球化的开放一体化主要趋势将不会改变,我们相信复兴集团一直在做正确的事情,并将继续这样做。"

SOURCE Fosun

资料来源:中国平安

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发